1143 related articles for article (PubMed ID: 25616707)
1. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
2. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter inhibition in the treatment of diabetes: sweetening the pot.
Alvarez CA; Neeland IJ; McGuire DK
Diab Vasc Dis Res; 2015 Mar; 12(2):74-7. PubMed ID: 25690133
[No Abstract] [Full Text] [Related]
4. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
5. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus.
Abdul-Ghani MA; Norton L; DeFronzo RA
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F889-900. PubMed ID: 26354881
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.
Inzucchi SE; Zinman B; Wanner C; Ferrari R; Fitchett D; Hantel S; Espadero RM; Woerle HJ; Broedl UC; Johansen OE
Diab Vasc Dis Res; 2015 Mar; 12(2):90-100. PubMed ID: 25589482
[TBL] [Abstract][Full Text] [Related]
7. The Na
Koepsell H
Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
[TBL] [Abstract][Full Text] [Related]
8. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
9. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
10. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
11. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
[TBL] [Abstract][Full Text] [Related]
12. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibitors and renal function.
Med Lett Drugs Ther; 2016 Jul; 58(1499):91-2. PubMed ID: 27403782
[No Abstract] [Full Text] [Related]
14. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
15. Renoprotective Effects of SGLT2 Inhibitors: Beyond Glucose Reabsorption Inhibition.
Tsimihodimos V; Filippatos TD; Filippas-Ntekouan S; Elisaf M
Curr Vasc Pharmacol; 2017; 15(2):96-102. PubMed ID: 27748201
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus.
Dailey GE
Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032
[TBL] [Abstract][Full Text] [Related]
17. SGLT2 Inhibitors: Glucotoxicity and Tumorigenesis Downstream the Renal Proximal Tubule?
Bertinat R; Nualart F; Yáñez AJ
J Cell Physiol; 2016 Aug; 231(8):1635-7. PubMed ID: 26661279
[TBL] [Abstract][Full Text] [Related]
18. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
Rajeev SP; Cuthbertson DJ; Wilding JP
Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
[TBL] [Abstract][Full Text] [Related]
19. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2.
Ohgaki R; Wei L; Yamada K; Hara T; Kuriyama C; Okuda S; Ueta K; Shiotani M; Nagamori S; Kanai Y
J Pharmacol Exp Ther; 2016 Jul; 358(1):94-102. PubMed ID: 27189972
[TBL] [Abstract][Full Text] [Related]
20. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]